# Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion

> **NIH NIH UG1** · THE EMMES COMPANY, LLC · 2021 · $283,361

## Abstract

PROJECT ABSTRACT
The CD34RVO trial is a phase I/II randomized, prospective, double-masked, sham-controlled study with cross-
over to determine the feasibility, safety and potential efficacy of intravitreal injection of autologous adult CD34+
cells from bone marrow in subjects with vision loss from retinal vein occlusion. The Emmes Corporation will
serve as the Data Coordinating Center (DCC) for the CD34RVO study. In collaboration with the Study Chair,
the DCC provides overall study leadership to CD34RVO mainly in areas of data management, statistical and
operational support to include: statistical leadership in the study design; interim safety and study data reports
to the Data and Safety Monitoring Committee; preparation of study results in collaboration with other study
leadership and dissemination of findings; design and implementation of a web-based data collection system;
support of the Clinical Center from study initiation to study closeout, including site monitoring to ensure proper
conduct of the study and good quality data; provision of quality assurance and quality control oversight, and
provision of administrative and meeting support.

## Key facts

- **NIH application ID:** 10176505
- **Project number:** 5UG1EY028517-04
- **Recipient organization:** THE EMMES COMPANY, LLC
- **Principal Investigator:** Jennifer Bacik McCormack
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $283,361
- **Award type:** 5
- **Project period:** 2018-06-15 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10176505

## Citation

> US National Institutes of Health, RePORTER application 10176505, Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion (5UG1EY028517-04). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10176505. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*